Novartis Triumphs At EMA With Jetrea, But Merck Has Suspension of Three Merck Products Confirmed
This article was originally published in The Pink Sheet Daily
Executive Summary
The EMA has given the nod to Novartis subsidiary Alcon’s vitreomacular traction drug Jetrea and agreed to an indication extension for its Ilaris product to treat gouty arthritis. EMA’s Committee for Medicinal Products for Human Use also confirmed a recommendation to suspend the marketing authorizations of three Merck Sharp & Dohme products used to treat adults with dyslipidemia.